Entropy Technologies LP Buys Shares of 74,691 Gilead Sciences, Inc. $GILD

Entropy Technologies LP purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 1st quarter, Holdings Channel reports. The institutional investor purchased 74,691 shares of the biopharmaceutical company’s stock, valued at approximately $10,410,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the 4th quarter worth $25,000. Vermillion & White Wealth Management Group LLC increased its position in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares in the last quarter. Quattro Advisors LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at about $26,000. Wealth Preservation Advisors LLC boosted its holdings in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in Gilead Sciences in the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on GILD. Royal Bank Of Canada cut their price objective on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Rothschild & Co Redburn dropped their target price on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Morgan Stanley cut their price target on shares of Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 8th. Finally, HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $158.33.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the sale, the insider directly owned 124,234 shares in the company, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 77,000 shares of company stock valued at $9,978,740. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $129.31 on Friday. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The company’s 50 day moving average is $129.55 and its 200 day moving average is $135.50. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The company has a market cap of $160.55 billion, a PE ratio of 17.62 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same period in the previous year, the business posted $1.81 EPS. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post -0.77 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.